BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space - 2Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
- 3Why do people have baby teeth and adult teeth?
- 4Nvidia Share Price Could Be Hit Hard By Iran War
- 5The beauty advent calendar boom is here. Sephora kids are all in.
- Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses
- Posts falsely claim Netanyahu video fabricated to cover up his death
- FDA approves Wegovy pill for weight loss: What to know
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- NASA is shooting for the moon. A guide to the Artemis II mission
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
